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Chronic skin colonization with Staphylococcus aureus is a
well-known feature in atopic dermatitis. The aim of this
study was to develop a human-SCID mouse model to
analyze the possible role of bacterial superantigens in
human allergic immune responses under in vivo condi-
tions. SCID mice were reconstituted with peripheral
blood mononuclear cells (between 2 and 9 H 107 cells
per mouse) from atopic dermatitis patients sensitized to
house dust mite allergen (Der p). Total and Der p specific
antibody production required the following conditions:
(i) injection of Der p; (ii) presence of CD141 antigen-
presenting cells; and (iii) IL-4 as shown by the inhibitory
effect of human soluble IL-4 receptor on immunoglobulin
E production. This model was used to study the immuno-
modulatory effects of the superantigen staphylococcal
enterotoxin B in comparision with Der p. In intraperi-
S taphylococcus aureus and streptococcus produce a large family ofproteins known as superantigens, which include staphylococ-cal enterotoxins, e.g., staphylococcal enterotoxin B (SEB),staphylococcal toxic shock syndrome toxin-1, and strepto-coccal pyrogenic exotoxins (Marrack and Kappler, 1990;
Mollick et al, 1993). Unlike conventional antigens, superantigens do
not require processing by antigen-presenting cells, because they are
stimulatory in their native state and engage a sizeable fraction of the
T cell compartment via direct binding and stimulation of T cell
receptor Vβ elements (Dellabona et al, 1990; Herman et al, 1991).
Atopic dermatitis (AD) represents a main manifestation of the atopic
syndrome and is characterized as a chronic inflammatory skin disease
associated with pruritus and elevated serum immunoglobulin E (IgE)
levels. Local infiltration of activated CD41 T cells is a hallmark in the
immunopathogenesis of the disease (Zachary et al, 1985; Lever et al,
1987; Van Joost et al, 1992). Acute AD lesions are characterized by
the presence of T cells producing classical type-2 cytokines including
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toneally reconstituted human-SCID mice, topical treat-
ment was ineffective in inducing skin inflammation.
Therefore, additionally to intraperitoneal transfer, peri-
pheral blood mononuclear cells from atopic donors were
also injected intradermally. Such reconstituted SCID
mice were then exposed via the skin to either Der p,
staphylococcal enterotoxin B, or a combination of both.
Maximal effects on epidermal inflammation and dermal
T cell infiltration were obtained with staphylococcal
enterotoxin B and Der p. Staphylococcal enterotoxin B
alone was less effective and Der p only stimulated dermal
T cell infiltration. These findings support the hypothesis
that bacterial superantigens can act as trigger factors in
allergic skin inflammation. Key words: atopic dermatitis/
house dust mite allergen/SEB. J Invest Dermatol 110:224–
231, 1998
interleukin (IL)-4 and IL-5 (Sager et al, 1992; van Reijsen et al, 1992).
In chronic skin lesions, a shift from elevated IL-4/IL-5 production to
decreased levels of IL-4 and increased production of interferon (IFN)-
γ was observed (Grewe et al, 1994, 1995; Werfel et al, 1996). T cell
activation is associated with an imbalance in cytokine production
resulting in increased production of IL-4 and reduced production of
IFN-γ (Reinhold et al, 1990; Renz et al, 1992b; Jujo et al, 1992). T
cell immunity to aeroallergens such as house dust mite allergen (Der
p) is thought to play an important role in the pathogenesis of AD:
allergen-specific T cell lines and clones can be generated from dermal
and epidermal skin lesions. Less than 3% of the infiltrating T cells are
allergen-specific, however (Sager et al, 1992; Werfel et al, 1996).
Superantigens may act as an additional trigger factor in the development
of skin inflammation. Staphylococcus aureus can be isolated from skin
lesions in about 95% of all AD patients as compared with about 5% of
nonatopic individuals (Leyden et al, 1974); S. aureus on inflamed AD
lesions without clinical superinfection can reach 107 colony forming
units per square centimeter on lesional skin (Hauser et al, 1985); S.
aureus colonization can cause severe exacerbation of the disease in
many patients and anti-staphylococcal therapy is beneficial in severe
cases (Leyden et al, 1974). Despite this circumstantial evidence, a clear
causal relationship has not yet been established. In order to define the
role of superantigens in allergy, an experimental in vivo model of a
humanized SCID (hu-SCID) mouse was developed.
Mice homozygous for the scid mutation (SCID mice) are severely
deficient in functional B and T lymphocytes. Thus, SCID mice are
unable to reject allogeneic and xenogeneic tissue transplants. Several
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Figure 1. Dose and time dependent stimulation of hu-IgE antibody responses in hu-SCID mice. PBMC were prepared from one atopic donor (total
IgE 5 21.4 µg per ml) who was sensitized to Der p as indicated by an anti-Der p IgE antibody concentration of 220 ng per ml and positive skin prick test
reactions. Indicated cell numbers were i.p. injected into nine SCID mice together with Der p. On day 8, mice received an additional boost with Der p. Blood
was drawn at indicated time points and total (A) and allergen-specific (B) hu-IgE antibody titers were determined by FEIA. The mean 6 SD is expressed from
three independently performed experiments.
studies report that SCID mice reconstituted with peripheral blood
mononuclear cells (PBMC) from atopic patients sensitized to Der p,
produced human-IgE when stimulated in the presence of adjuvant (Ito
et al, 1992; Pestel et al, 1994; Spiegelberg et al, 1994; Gagnon et al,
1995). In models of immuno-competent mice we showed that allergen
sensitization stimulated an allergic immune response in the absence of
adjuvant with increased production of IgE (Renz et al, 1992a). In this
study we analyzed the conditions for human allergen-specific IgE
production in reconstituted human SCID mice. We then examined
the effect of topical aeroallergen and superantigen treatment on
development of skin inflammation in this model.
MATERIALS AND METHODS
Study groups AD patients (n 5 13) sensitized to Der p were identified by
positive skin prick test reactions and elevated serum IgE antibody titers. Skin
prick tests were performed with standard solutions obtained from ALK-Scherax
(Hamburg, Germany). Human serum IgE antibody titers were measured
by Fluorescence-Enzyme-Immuno-Assay (FEIA) (Pharmacia CAP System,
Pharmacia, Uppsala, Sweden). Atopic patients responded to Der p with a wheal
ù 10 mm in diameter and antibody titers ù 410 ng per ml for total IgE and
ù 20 ng per ml for anti-Der p IgE. All patients suffered from severe AD based
on the criteria by Hanifin and Rajka (1980). Non-atopic volunteers (n 5 4)
showed total serum IgE concentrations of ø 17 ng per ml and anti-Der p IgE
of ø 0.8 ng per ml, and they had negative skin test reactions.
Animals SCID mice (C.B-17 scid/scid) were obtained from Bomholtgard
(Ry, Denmark) and were maintained under pathogen-free conditions. Animals
between 8 and 12 wk of age were screened for leakage by measurement of
mouse IgG antibodies in the serum before the onset of experiments.
Preparation of PBMC Heparinized blood (200–250 ml) was collected from
donors sensitized or nonsensitized to Der p and mononuclear cells were purified
from heparinized blood by Lymphoprep (Nycomed, Oslo, Norway) density
gradient centrifugation as previously described (Nasert et al, 1996).
Reconstitution of SCID mice with human PBMC SCID mice were
injected intraperitoneally (i.p.) with 2–9 3 107 PBMC together with 100 µg
purified house dust mite extract referred to as Der p (Alk-Scherax, Hamburg,
Germany). The extract was calibrated based on the amount of Der p 1 and
diluted in phosphate-buffered saline (PBS). One hundred micrograms of the
extract contained 5 µg Der p 1. Eight days later, SCID mice received an
additional i.p. allergen boost (100 µg Der p per injection). Between day 22
and day 28, total and allergen-specific human-IgE antibody titers in hu-SCID
mice were measured by FEIA (Pharmacia CAP System).
Assessment of cytokine production after in vivo treatment with
SEB SCID mice were injected i.p. with 9 3 107 PBMC together with Der
p (100 µg per injection), SEB (Serva-Toxin Technology, Heidelberg, Germany)
(50 ng per injection), or a combination of both. Eight days later, SCID mice
received an additional allergen or SEB boost or a combination of both, as
described above. To assess cytokine production, human PBMC were recovered
from reconstituted SCID mice by day 22. Human lymphocytes were collected
from the peritoneal cavity by washing with sterile, ice-cold PBS and resuspended
after centrifugation (3000 rpm, 10 min) in PBS. Four 3 106 PBMC per well
were incubated in the presence of concanavalin A (2.5 µg per ml) for 48 h.
Cell-free culture supernatants were harvested and production of IL-4, IL-5,
and IFN-γ was analyzed by an enzyme-linked immunosorbent assay technique
as described below.
Treatment of human-SCID mice with soluble IL-4 receptor (sIL-
4R) Human PBMC reconstituted SCID mice were treated with human
recombinant sIL-4R (150 µg per mouse per application) or with murine sIL-
4R (150 µg per mouse per application). Human recombinant sIL-4R and
murine sIL-4R were kindly provided by Dr. K. Enssle (Behringwerke,
Marburg, Germany).
Topical treatment of SCID mice PBMC from AD patients or nonatopic
individuals were injected i.p. (9 3 107 PBMC per mouse) together with Der
p as described above. On day 14, 3 3 107 PBMC derived from the same donor
were injected intradermally (i.d.). Every day between days 15 and 19 the
epidermal lipid barrier was removed by scratching (310) with 70% ethanol
followed by topical application of 200 µl solution containing either 100 µg
Der p per application or 50 ng SEB per application, or a mixture of both. As
previously shown (Saloga et al, 1994), and as also reproduced in this study,
scratching alone did not cause a mechanic trauma. On day 20, histologic analysis
of skin sections was performed.
Isolation and removal of CD141 cell subset CD141 antigen-presenting
cells were removed from PBMC by multi-step cell purification protocol using
immunomagnetic beads, and the purity of cells was assessed by flow cytometry
using monoclonal antibodies against CD3, CD4, CD8, and IgE as previously
described (Nasert et al, 1996).
Culture assay for in vitro Ig production and cytokine production To
assess immunoglobulin production, 4 3 106 PBMC per well were incubated
in 24 well flat bottom tissue culture plates (Greiner, Solingen, Germany)
diluted in tissue culture medium. Culture medium consisted of RPMI 1640
supplemented with 10% heat-inactivated fetal calf serum (Behringwerke), 2 mM
glutamine, 100 IU penicillin per ml, 100 µg streptomycin (Biochrom, Berlin,
Germany) per ml, and 0.2 µg amphothericin B (Gibco BRL, Eggenstein,
Germany) per ml. Cells were incubated with 700 ng Der p per ml, 50 ng SEB
(Sigma, Deisenhofen, Germany) per ml, or a combination of both. After 10 d,
cell free culture supernatants were harvested and IgE production was measured
by FEIA (Pharmacia CAP System). To assess cytokine production, cell free
culture supernatants were harvested after 48 h and analyzed for IL-4, IL-5,
and IFN-γ production by enzyme-linked immunosorbent assay as previously
described (Nasert et al, 1996).
Histologic and ultrastructural evaluation Skin biopsies were prepared and
fixed in 4% formaldehyde. Three micrometer paraffin-embedded sections were
stained with hematoxylin and eosin or incubated with normal mouse serum
followed by incubation with monoclonal antibodies directed either against
human T lymphocytes (M-742, 1:100, Dako, Hamburg, Germany) or against
human B lymphocytes (M-754, 1:20, Dako) for 30 min at 37°C. Immunostaining
was performed by alkaline phosphatase:anti-alkaline phosphatase technique.
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Negative controls using Tris-buffer instead of antibodies were free from
immunolabeling. The dermal infiltrate was evaluated in a blinded fashion by
an independent investigator. Three skin areas were randomly selected in each
section and numbers of infiltrating human T cells were scored as ,20 cells per
mm2 dermis, 20–100 cells per mm2 dermis, or .100 cells per mm2 dermis.
Statistical analysis Results are presented as mean values 6 SD, unless
otherwise stated. Mann–Whitney U test (exact test, single sided) was used to
determine the level of difference between animal groups.
RESULTS
Production of human IgE in SCID mice reconstituted with PBMC
from atopic patients SCID mice were reconstituted with PBMC from
atopic and nonatopic individuals. Figure 1 illustrates a representative
dose response experiment performed with cells from one of three AD
patients (total IgE 21,400 ng per ml; anti-Der p IgE 220 ng per ml).
Transfer of at least 4 3 107 PMBC per mouse resulted in the production
of total human-IgE antibody titers reaching maximal levels between
day 14 and day 22. Induction of allergen-specific human-IgE required
transfer of more than 4 3 107 PMBC per mouse. The kinetic of anti-
Der p human-IgE antibody titers paralleled total human-IgE antibody
titers peaking also around day 22.
Figure 2 compares total and allergen-specific IgE/IgG antibody
titers from several sets of independently performed experiments. There
was a positive correlation between total (r 5 0.700) (Fig 2A) and
allergen-specific (r 5 0.626) (Fig 2B) human-IgE concentrations in
the serum of the human donors and in reconstituted SCID mice. In
contrast, no correlation was found between human allergen-specific
IgG antibody titers in the serum of atopic cell donors and reconstituted
hu-SCID mice.
To assess whether an allergen-specific IgE response could also be
induced in mice reconstituted with nonatopic PBMC, cells were
prepared from healthy nonatopic individuals (total IgE ø 17 ng per
ml, anti-Der p IgE ù 0.8 ng per ml) and transferred into SCID
mice as described earlier. After transfer of a comparable number of
mononuclear cells, total IgE production never exceeded 4 ng per ml
and allergen-specific IgE could not be detected. These results indicate
that nonatopic PBMC could not be converted into IgE producing
cells even when mice received an allergen challenge. Irrespective of
whether SCID mice were reconstituted with PBMC from atopic or
nonatopic cell donors, human-IgG antibodies were detectable on day
28 (1.9 6 1.3 mg per ml), indicating that human T and B cells
remained functional in SCID mice.
It was then determined whether the allergen challenge was required
in order to mount an allergen-specific immune response in hu-SCID
mice reconstituted with atopic PBMC. Although patients had high
titers of circulating allergen-specific IgE antibodies, no anti-Der p
specific antibodies could be detected in animals without allergen
administration, indicating that production of specific IgE required
continuous exposure to the allergen even in atopic patients (data not
shown). Although most cell-donors were sensitized to a wide range of
inhalant allergens as indicated by the presence of specific IgE antibodies
to birch pollen allergen (Fig 3) and other allergens (data not shown),
only anti-Der p IgE and not anti-birch pollen allergen IgE or IgE
directed against other inhalant allergens was measurable in animals
boosted with Der p (Fig 3).
It is possible that human-IgE production in reconstituted atopic
SCID mice was caused by a recall of transferred human-IgE positive
and/or memory B cells. In this case, removal of CD141 antigen-
presenting cells should not disturb the capacity to mount an IgE
antibody response. CD141 cells were removed from atopic PBMC by
immunomagnetic beads technique and transferred into SCID mice. In
parallel, SCID mice were treated with unfractioned PBMC derived
Figure 2. IgE titers in hu-SCID mice correlate with serum IgE of atopic
patients. Human PMBC, prepared from atopic donors (n 5 12) sensitized
against house dust mite (Der p) (anti-Der p IgE ù 20 ng per ml), were
transferred together with Der p (100 µg Der p per mouse) into the peritoneal
cavity of SCID mice (n 5 16, 30–903106 PBMC per mouse). On day 8, mice
received an additional injection of Der p. Blood was drawn between days 22
and 28 and total (A), anti-Der p IgE (B), and anti-Der p IgG (C) antibody
titers were measured by FEIA (Pharmacia CAP System) in the serum and
compared with the IgE/IgG antibody titers in the serum of the atopic donor.
Each point represents serum IgE values of a patient and the corresponding
serum IgE levels from SCID mice reconstituted with cells from the same donor.
VOL. 110, NO. 3 MARCH 1998 HU-SCID MODEL FOR SKIN INFLAMMATION 227
Figure 3. Induction of allergen-specific IgE depends on the allergen boost. SCID mice were reconstituted with 9 3 107 human PBMC per mouse as
described in Fig 1. Anti-Der p IgE (A) and anti-birch pollen allergen IgE (B) antibody titers were measured by FEIA (Pharmacia CAP System). The allergen-
specific IgE antibody titers in the serum of reconstituted SCID mice in comparision to the antibody titers of the human donors are indicated.
Figure 4. Induction of hu-IgE in SCID mice is dependent on CD141 antigen-presenting cells. CD141 antigen-presenting cells were separated from
atopic PBMC by immuno-magnetic beads technique. Expression of CD14, CD3, CD4, and IgE on B cells was analyzed by fluoroscence activating cell sorting
analysis. SCID mice were reconstituted with human PBMC as described in Fig 1. Total human-IgE antibody titers were measured by FEIA (Pharmacia CAP
System). Part (A) shows the distribution of cell subsets before and after CD14 depletion from three individual atopic patients that were transferred into SCID mice,
and (B) represents total IgE antibody titers examined in reconstituted SCID mice on day 22.
from the same donor. Figure 4(A) illustrates the distribution of
transferred cell populations indicating a similar distribution of CD3,
CD4, and IgE positive cell subsets except for the presence of CD141
cells. Figure 4(B) shows the corresponding total human-IgE antibody
titers of these animals 22 d after transfer. The results indicate that in
the absence of CD141 antigen-presenting cells, human-IgE antibody
synthesis was markedly reduced, suggesting an important role of
CD141 cell subsets in IgE production even from cell donors that were
sensitized to this allergen.
IL-4 induces human B cell maturation and IgE synthesis in hu-
SCID mice Because IgE production is known to depend to a large
extent on the production of IL-4, we examined whether treatment
with an IL-4 binding protein (recombinant human sIL-4R) would
inhibit allergen induced IgE production in vivo. In a ‘‘prophylactic’’
approach, treatment was started at the time of cell transfer and continued
throughout the experimental protocol (on days 1, 2, and 3, and again
on days 7, 8, and 9). In a second protocol, ‘‘therapeutic’’ approach hu-
SCID mice were treated with human sIL-4R between days 9 and 13
only. Control hu-SCID mice were treated with recombinant murine
sIL-4R, a protein that does not bind to human IL-4 (Rudolphi et al,
1993). ‘‘Prophylactic,’’ but not ‘‘therapeutic,’’ treatment with human-
sIL-4R resulted in reduced levels of human-IgE antibody titers
(Table I). These findings suggest that in this system IgE could be
inhibited only when sIL-4R treatment was started early; however, sIL-
4R was not sufficient to completely prevent production of IgE in all
recipient mice.
In vivo SEB treatment reduces allergen-induced IgE
synthesis Because this animal system seems to reproduce events that
contribute to increased IgE antibody production in humans, we used
it to assess the immunomodulatory role of superantigen in triggering
T cell functions under in vivo conditions. As shown above, transfer of
PBMC from AD patients followed by i.p. challenge with Der p
resulted in measurable total IgE levels (Table II). Significantly lower
levels of human-IgE production were detected when mice were
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Table I. Prophylactic but not therapeutic treatment with
hu-sIL-4R inhibits hu-IgE production in
hu-SCID micea
Treatment of
hu-PBMC SCID Total hu-IgE
Treatment Atopic donor mice with: (ng per ml)
Prophylactic 01 mu-sIL-4R 147.6
hu-sIL-4R 6.4 (4%)b
02 mu-sIL-4R 76.3
hu-sIL-4R 50.4 (66%)
Therapeutical 10 mu-sIL-4R 56.9
hu-sIL-4R 52.9 (93%)
11 mu-sIL-4R 49.6
hu-sIL-4R 45.5 (92%)
12 mu-sIL-4R 72.7
hu-sIL-4R 80.4 (111%)
aNine 3 107 human PBMC derived from five atopic donors (total IgE ù
5000 ng per ml) were injected in combination with Der p into the peritoneal
cavity of SCID mice as described in Materials and Methods. Eight days later hu-
SCID mice received an additional allergen boost with Der p. Two mice were
reconstituted with cells from the same donor. One mouse was then treated with
murine (mu) recombinant sIL-4R (150 µg per application), the other received
human (hu) recombinant sIL-4R (150 µg per application) by intraperitoneal
injection. Two strategies of sIL-4R treatment were performed. In a ‘‘prophylactic’’
approach, mice were treated on days 1, 2, and 3, and again on days 7, 8, and 9.
In the ‘‘therapeutic’’ protocol, mice were treated on days 9, 10, 11, 12, and 13
only. On day 22 total human-IgE antibody titers in hu-PBMC SCID mice were
determined by FEIA.
bPercentage of hu-IgE production in hu-sIL-4R treated mice compared with
treatment with control protein (mu-sIL-4R, calculated as 100%).
Table II. Immunoglobulin and cytokine production in
hu-SCID mice and AD patientsa
Immunoglobulin and cytokine production in
response to:
Der p SEB Der p 1 SEB
in vivo total IgE 298 6 203b 49 6 39 7 6 6*
(ng per ml)
anti-Der p IgG 4.5 6 2.2 4.3 6 4.0 ø2*
(µg per ml)
ex vivoc IL-4 ø10 ø10 18.6 6 4.5*
(pg per ml)
Il-5 ø30 ø30 44.5 6 6.4*
(pg per ml)
IFN-γ ø100 140 6 5 240 6 1*
(pg per ml)
in vitrod IL-4 ø10 22 6 9 13 6 3*
(pg per ml)
Il-5 ø40 778 6 174 534 6 82*
(pg per ml)
IFN-γ ø30 4706 6 2240 3410 6 2292*
(pg per ml)
aNine 3 107 PBMC derived from two AD patients were injected intraperitoneally in
combination with Der p (n 5 3), SEB (n 5 3), or both (n 5 3); 8 d later mice received
an i.p. booster injection with Der p, SEB, or both as described in Materials and Methods.
Blood was drawn on day 22 and total and allergen-specific IgE antibody titers were measured.
bResults are shown as mean 6 SD. Der p treated versus Der p 1 SEB treated group,
*p ø 0.05 (Mann–Whitney U test).
cAfter 22 d human PBMC were recovered from reconstituted SCID mice and cultured
for 48 h in the presence of Concanavalin A (2.5 µg per ml). IL-4, IL-5, and IFN-γ
production was measured in cell-free culture supernatant.
dBefore transfer into SCID mice 4 3 106 PBMC derived from six AD patients were
cultured in the presence of Der p (5 µg per ml), SEB (20 ng per ml), or both for the
determination of in vitro cytokine production. Cell-free culture supernatants were collected
after 48 h and cytokine production was measured.
Table III. Effect of intraperitoneal and intradermal cell transfer on development of Der p- and SEB-induced skin inflammation
Cell transfera
Dermal T cell infiltrate
No. of exp. i.p. i.d. Topical treatmentb Epidermal changes (cells per mm2 dermis)
n 5 4 – – Der p 1 SEB – ,20
n 5 4 1 – Der p 1 SEB – ,20
n 5 4 – 1 Der p 1 SEB acanthosis 20–100
n 5 3 1 1 Der p 1 SEB acanthosis, parakeratosis, spongiosisc .100
aSCID mice received either PBMC from the same AD patient or PBS i.p. and i.d. as described in Materials and Methods.
bBetween days 15 and 19 all mice were topically treated with a solution of Der p plus SEB as described in Materials and Methods. On day 20, animals were sacrificed, skin sections were
performed and epidermal changes and dermal T cell infiltrate were evaluated as described in Materials and Methods.
cIn two experiments, acanthosis, spongiosis, and parakeratosis were observed, whereas acanthosis alone was found in one experiment.
Table IV. Effect of Der p and SEB on development of skin inflammation
Cell transfera
Dermal T cell infiltrate
No. of exp. i.p. i.d. Topical treatmentb Epidermal changes (cells per mm2 dermis)
n 5 3 1 1 PBS – ,20
n 5 4 1 1 Der p – 20–100
n 5 4 1 1 SEB acanthosis, parakeratosis, spongiosis 20–100
n 5 3 1 1 Der p 1 SEB acanthosis, parakeratosis, spongiosis .100
aSCID mice received PBMC from the same AD patient i.p. (day 1) and i.d. (day 14). Between days 15 and 19 all mice were topically treated with PBS, Der p, SEB, or a combination
of Der p plus SEB as described in Materials and Methods. On day 20, animals were sacrificed, skin sections were hematoxylin and eosin stained or immunolabeled with an antibody directed
against human T cells. Epidermal changes and dermal T cell infiltrate were evaluated as described in Materials and Methods.
reconstituted with cells from the same donor and i.p. treated with SEB
and Der p. In addition, there was a tendency for levels of IgE to be
lower in mice treated with SEB than in those treated with Der p
alone. Anti-Der p IgG synthesis was not affected in animals treated
with SEB. In contrast, anti-Der p IgG synthesis was significantly
reduced (p , 0.001) in animals treated with SEB and Der p. To
determine underlying causes of this effect, cytokine production was
assessed in vitro with human cells recovered by peritoneal lavage.
Pilot experiments indicated that the cells required additional in vitro
stimulation with mitogen in order for any interleukin secretion in
culture supernatant to be detectable (data not shown). As indicated in
Table II, T cells from mice that received Der p did not produce IL-
4 (ø10 ng per ml) when restimulated ex vivo. In contrast, SEB
treatment of hu-SCID mice resulted in measurable IFN-γ production.
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Furthermore, in Der p exposed mice treated with SEB we found a
synergistic enhancing effect on IFN-γ synthesis and IL-5 production. A
similar cytokine pattern was obtained when atopic PBMC were
stimulated in vitro with Der p and/or SEB. SEB markedly enhanced
IL-5 and IFN-γ production, with little effect on IL-4 production.
Topical SEB treatment induces cutaneous inflammation These
data indicate that SEB treatment of hu-SCID mice with atopic
lymphocytes caused a shift in immune responses with inhibition of
IgE and, on the other hand, stimulation of IFN-γ and IL-5 production.
Because these two cytokines were found upregulated in chronic
inflammatory lesions (Hamid et al, 1994), we examined whether topical
Der p and SEB treatment would trigger an allergic inflammatory
response of the skin. Topical application was carried out according to
a previously published protocol (Saloga et al, 1994). Epidermal and
dermal skin inflammation were observed when i.p. reconstituted SCID
mice received an additional intradermal injection of PBMC from the
same AD donor 14 d before topical application of Der p plus SEB was
started (Table III). In contrast, topical treatment of mice without cell
injection or with either i.p. or i.d. cell injection did not produce an
equivalent inflammatory response.
This model was then utilized to assess whether the superantigen
and/or the allergen were responsible for these effects. For this purpose
i.p. plus i.d. injected SCID mice from the same AD donor were
topically treated with either PBS, Der p, SEB, or a combination of
Der p and SEB. Application of PBS alone produced no pathologic
changes in epidermis and only a few human T cells were observed in
the dermis (,20 cells per mm2 dermis) (Table IV). This result also
confirms previous data (Saloga et al, 1994) that shows that shaving and
scratching of the skin with 70% ethanol did not cause a mechanic
trauma. Application of Der p to the skin triggered moderate dermal T
cell infiltrate (20–100 cells per mm2 dermis), without changes in the
epidermis (Fig 5A, D). When SEB was applied to the skin a similar
cellular infiltrate (20–100 cells per mm2 dermis) was observed in
the dermis. In addition the epidermis showed signs of acanthosis,
parakeratosis, and spongiosis (Fig 5B, E). Following the simultaneous
application of SEB and Der p, a marked human T cell infiltrate (.100
cells per mm2 dermis) in the dermis was observed (Fig 5C, F). In
addition to T cell infiltration, similar epidermal changes were observed
as with SEB alone.
In order to examine whether this type of response depended on
transfer of AD PBMC or could also be induced with nonatopic PBMC,
nonatopic PBMC SCID mice were also treated topically with Der p
plus SEB. The results from these experiments are summarized in
Table V. In nonatopic PBMC SCID mice the epidermis remained
normal and few human T cells (,20 cells per mm2 dermis) were
detected in the dermis. In contrast, AD PBMC SCID mice developed
the type of skin inflammation described above (Fig 5C, F; Table IV).
DISCUSSION
In contrast to other models of hu-SCID mice of (allergen-specific) Ig
antibody responses (Ito et al, 1992; Pestel et al, 1994; Spiegelberg et al,
1994; Gagnon et al, 1995), we set out to stimulate allergen-specific
IgE antibody production in the absence of any adjuvant. Adjuvants
such as aluminum hydroxide are known to provide nonspecific
inflammatory signals (Holt et al, 1991) and it is difficult to distinguish
between direct effects caused by the allergen itself and nonspecific
potent immune-enhancing effects induced by adjuvants. In our in vivo
model of human allergic immune responses, SEB was identified as a
potent immune-modulator that promoted development of a cutaneous
inflammatory response with simultaneous inhibition of systemic IgE
production.
Several factors and components were found to be necessary for an
allergen-specific antibody response in this hu-SCID model. First,
allergen exposure was necessary to trigger IgE production, even when
PBMC from patients with high IgE serum levels were transferred into
SCID mice. Although IgE-positive B cells were present in the injected
cell population, restimulation with allergen was necessary to trigger
IgE production, because in the absence of allergen no IgE antibody
titers were detected. In this hu-SCID mouse system, induction of
Figure 5. Topical superantigen triggers dermal T cell infiltration in hu-
SCID mice. PBMC were prepared from an AD patient and injected i.p. (day
1) and i.d. (day 14) as described in Materials and Methods. Between days 15 and
19 a solution of Der p (A, D) (100 µg Der p per application), SEB (B, E)
(50 ng SEB per application), or a combination of both (C, F) was applied to
the skin. One day after the last treatment, animals were sacrificed and skin
histology was evaluated. (A, B, C) Hematoxylin and eosin staining; (D, E, F)
immuno-histologic staining with anti-human T cell antibody as described in
Materials and Methods. One of three similar experiments are shown. Scale
bar, 100 µm.
allergen-specific IgE was always paralleled by high titers of total IgE.
In addition to allergen-specific IgE, enhancement of total IgE also
required an allergen challenge and was not observed in the absence of
allergen injections. The IgE antibody titers measured in SCID mice
paralleled IgE titers of allergic cell donors. This suggests that the hu-
SCID mouse model of human-IgE production induced by allergen
challenges in the absence of adjuvant is suitable for the study of certain
aspects of the allergic immune response.
The allergen-specific immune response involves CD14 positive
antigen-presenting cells. It is assumed that antigen-presenting cells vary
in their ability to induce type 1 versus type 2 responses: macrophages
tend to favor the induction of type 1 cells (Gajewski et al, 1991). We
initially hypothesized that B cells would be effective inducers of an
allergen-specific (type 2) immune response, because it has been shown
that B cells are much more effective at promoting IL-4 production
than macrophages (Schmitz et al, 1993). Surprisingly, after removal of
CD14 positive cells, IgE production was stimulated to a much lesser
extent even when equal numbers of T and B cells were transferred
from the same allergic cell donor into SCID mice. It is possible that
in vivo allergen processing and presentation by macrophages and/or
dendritic cells provide important costimulatory signals that could not
be delivered by B cells. Although in two of the three donors the
absolute numbers of IgE positive B cells were slightly reduced after
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Table V. Effect of non-atopic PBMC on development of skin inflammationa
Treatment
Dermal T cell infiltrate
No. of exp. i.p. i.d. Topical treatmentb Epidermal changes (cells per mm2 dermis)
n 5 3 AD AD Der p 1 SEB acanthosis, parakeratosis, spongiosis .100
n 5 4 Non-atopic Non-atopic Der p 1 SEB – ,20
aSCID mice received either PBMC from the same nonatopic or AD and were topically treated with Der p plus SEB as described in Table IV. On day 20, animals were sacrificed and
epidermal changes and dermal T cell infiltration were evaluated as described in Materials and Methods.
CD14 depletion procedure, it is unlikely that this significantly affected
in vivo IgE production, because it is known that a small number of
IgE committed B cells is sufficient to mount IgE production in SCID
mice (Pestel et al, 1994).
IL-4 represents an important cytokine that triggers the in vivo allergic
immune response at least during the initial stages. In order to assess
whether IL-4 was involved in the regulation of the allergic immune
response, hu-SCID mice were treated with recombinant human soluble
IL-4R, which binds specifically to human but not to murine IL-4
(Rudolphi et al, 1993). It has recently been shown that sIL-4R inhibits
several murine immune responses, including allergen-specific IgE/
IgG1 production, development of immediate-type skin test responses,
and prevention of increased airway responsiveness (Renz et al, 1995,
1996). Furthermore, the receptor downregulates human-IgE produc-
tion in vitro (Nasert et al, 1995). The data presented in this study provide
evidence that human sIL-4R also inhibits human-IgE production in
hu-SCID mice; however, when the receptor was administered in a
‘‘therapeutic’’ treatment regimen hardly any reduction was observed
compared with mice reconstituted with cells from the same patient
and treated with murine sIL-4R as a control protein. Only when the
receptor was administered at the time of cell transfer and continued
throughout the experimental protocol was there an inhibitory effect;
however, the suppression of IgE was never complete and residual IgE
antibody titers remained. These findings support recent data suggesting
that IL-4 is an early cytokine involved in IgE production, but other
cytokines, including IL-13, also play an important role in IgE synthesis
(Punnonen et al, 1993; McKenzie et al, 1993).
Because there is circumstantial clinical evidence that bacterial super-
antigens may trigger allergic inflammatory immune responses (reviewed
in Hauser and Orbea, 1993; Leung, 1995), particularly in AD, this hu-
SCID model was used to assess the effect of a prototypic superantigen
(SEB) on IgE production, cytokine release, and cutaneous inflammation.
If SEB contributes to allergic inflammation in AD patients, it should
enhance IgE production by its capacity to stimulate ‘‘pro-allergic’’ T
cells; however, experiments revealed an opposite effect, with low doses
of SEB inhibiting IgE. To analyze the underlying mechanism, cytokine
production was measured from AD lymphocytes prepared before and
after transfer into hu-SCID mice. Freshly prepared lymphocytes from
the same AD patients (Table II) responded with marked increases in
IL-4, IL-5, and IFN-γ production when they were stimulated with
SEB or a combination of SEB and Der p. Cells were then injected
intraperitoneally and harvested after about 3 wk for analysis of their
cytokine profile (Table II). In vivo treatment with SEB augmented
Der p-induced IL-5 and IFN-γ production in vitro. These two cytokines
play an important role in triggering allergic inflammatory immune
responses (Hamid et al, 1994). IL-5 is required for eosinophil recruit-
ment and survival, a cell population accumulating at the site of
inflammation (Broide et al, 1992) and contributing to tissue damage
associated with acute and chronic inflammation. On the other hand,
IFN-γ not only counteracts many of the IL-4 mediated immune
functions but also contributes to the development of inflammation by
causing monocytes and macrophages to release several potent pro-
inflammatory mediators.
In hu-SCID mice, recruitment of lymphocytes from the circulation
to the skin and back again could be abnormal. SCID mice lack a
lymphatic system, and it is still unclear how and to what extent human
T cells interact with murine adhesion molecules on vascular endothelial
cells. To bypass these limitations, Petzelbauer et al (1996) recently
reported on a hu-SCID model in which skin transplants provided an
autologous environment for previously transplanted T cells. We used
intradermal injection to bring human cells as close as possible to the
site of reaction in sufficient numbers. The highest degree of skin
inflammation was detected when a combination of both Der p
and SEB was applied. Marked morphologic changes in epidermis
(acanthosis, parakeratosis) were paralleled by T cell infiltration in the
dermis. These morphologic changes reflect some of the histopathologic
features in AD lesions (Murphy, 1995; Cohen et al, 1997). This implies
a functional interaction between epidermally applied superantigens and
allergens with the human T and B cell system in SCID mice. From
our experiments, however, it is impossible to delineate the exact
mechanism through which SEB activated the human T cells. It may
bind to murine major histocompatibility complex class II molecules
and allow bridging with human T cells, or, as human major histocom-
patibility complex class II expressing cells (activated T cells, monocytes,
B cells) were simultaneously injected, autologous activation of human
T cells would also be possible.
Taken together, these results demonstrate bi-directional in vitro effects
of SEB treatment. SEB inhibited IgE production, but a marked pro-
inflammatory effect was also observed following topical application on
the skin. Thus, this model of hu-SCID mice allows the in vivo analysis
of human allergic immune responses. Our results suggest that allergen
exposure, presence of CD141 antigen-presenting cells, and production
of IL-4 contribute to human allergen-specific IgE production in the
SCID model. This immune response can be altered by bacterial
superantigen in a bi-directional fashion resulting in suppressed IgE
production and enhanced local inflammatory immune reaction. Further
studies using the hu-SCID model will examine strategies of specific
immuno-intervention.
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